AMLX News

The IPO Market Flips from Boom to Bust in 2022 After the prior year’s record activity, the 2022 US IPO market ground to a halt as the war in Ukraine, a valuation correction in high-multiple stocks, historic interest rate hikes, and looming fears of a recession caused the narrowing IPO window to slam shut. 71...read more

While market conditions are still keeping the IPO window mostly closed, the year's large issuers are finding support, especially over the past few months. Excluding high-flying outlier HKD, just 15 IPOs have raised $100 million or more in 2022, and 13 (87%) are trading above issue. The group averages an impressive 29% return from offer, driven by... ...read more

IPO activity is still muted heading into the final stretch of 2022, weighed down by poor trading from new issuers. Despite challenging current market conditions, the energy and healthcare sectors have delivered solid trading recently, and are the only two averaging positive returns for the year. ...read more

Despite weak trading in the biotech sector, another drug developer is preparing to take on a challenging IPO market. Norovirus vaccine developer HilleVax (HLVX) plans to raise $175 million this week in the first major biotech IPO of the 2Q. Seven biotechs have gone public so far in 2022. While the group performed relatively well in the first quarter, returns...read more